{
    "clinical_study": {
        "@rank": "16606", 
        "arm_group": [
            {
                "arm_group_label": "Sodium Polystyrene Sulfonate", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours."
            }, 
            {
                "arm_group_label": "Silicified microcrystalline cellulose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral suspension of placebo blended with pigment to have the same appearance, taste, odor and mode of administration as SPS."
            }
        ], 
        "brief_summary": {
            "textblock": "It is hypothesized that SPS is more effective than placebo control (alternative hypothesis)\n      in lowering i-STAT potassium levels in subjects with i-STAT potassium levels between 5.0 -\n      6.5 mmol/l versus no difference between SPS and placebo control (null hypothesis)."
        }, 
        "brief_title": "Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperkalemia", 
        "condition_browse": {
            "mesh_term": "Hyperkalemia"
        }, 
        "detailed_description": {
            "textblock": "A total of 46 subjects with mild to moderate hyperkalemia (i-STAT potassium levels between\n      5.0-6.5 mmol/l, inclusive) will be randomized 1:1 in a double-blind fashion to receive\n      placebo or SPS (15g), administered tid with meals for 48 hours. Subjects will come back to\n      the clinic on Study Day 9 for an End of Study (EOS) visit.\n\n      Blood potassium levels will be evaluated by both i-STAT and the Local Laboratory prior to\n      the first dose on Study Days 1 and 2, 1, 2, and 4 hours after the first dose on Study Day 1,\n      1 and 4 hours after the first dose on Study Day 2 and prior to breakfast on Study Day 3,\n      after 48 hours of treatment.\n\n      Subjects who have i-STAT potassium levels > 6.5 mmol/l on Study Day 1 at the 4 hour post\n      Dose 1 time point will be withdrawn from the study and will receive standard of care. If the\n      i-STAT potassium value is between 6.1 and 6.5 mmol/l at the 4-hour post Dose 1 draw,\n      subjects will be kept in the clinic for another 90 minutes post Dose 2 and another blood\n      draw will be taken and an ECG will be performed. If the i-STAT potassium level is \u2265 6.2\n      mmol/l at this time point, the subject will be discontinued from the study and standard of\n      care will be instituted. If the i-STAT potassium level is < 6.2 mmol/l, and the ECG does not\n      show any of the ECG withdrawal criteria (see below), the subject will continue in the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of written informed consent.\n\n          -  Over 18 years of age.\n\n          -  Mean i-STAT potassium values between 5.0 - 6.5 mmol/l inclusive, at screening (Study\n             Day 0).\n\n          -  Previous participation in Clinical ZS-002 or ZS-003 protocol(s). However, subjects\n             cannot be enrolled in this study until at least 30 days have elapsed from their last\n             dose in study ZS-003.\n\n          -  Ability to have repeated blood draws or effective venous catheterization.\n\n          -  Women of childbearing potential must be using two forms of medically acceptable\n             contraception (at least one barrier method) and have a negative pregnancy test at\n             screening.\n\n        Women who are surgically sterile or those who are post-menopausal for at least 2 years are\n        not considered to be of child-bearing potential.\n\n        Exclusion Criteria:\n\n          -  Pseudohyperkalemia signs and symptoms, such as excessive fist clenching hemolyzed\n             blood specimen, severe leukocytosis or thrombocytosis.\n\n          -  Subjects treated with lactulose, Xifaxan or other non-absorbed antibiotics for\n             hyperammonemia within the last 7 days.\n\n          -  Subjects treated with resins (such as Sevelamer acetate), calcium acetate, calcium\n             carbonate, or lanthanum carbonate, within the last 7 days.\n\n          -  Subjects treated with Sodium Polystyrene Sulfonate (SPS; e.g. Kayexalate\u00ae) or ZS\n             (microporous, fractionated, protonated zirconium silicate) within the last 30 days.\n\n          -  Subjects with a life expectancy of less than 3 months.\n\n          -  Subjects who are HIV positive.\n\n          -  Subjects who are severely physically or mentally incapacitated and who in the opinion\n             of investigator are unable to perform the subjects' tasks associated with the\n             protocol.\n\n          -  Women who are pregnant, lactating, or planning to become pregnant.\n\n          -  Subjects with diabetic ketoacidosis.\n\n          -  Presence of any condition which, in the opinion of the investigator, places the\n             subject at undue risk or potentially jeopardizes the quality of the data to be\n             generated.\n\n          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.\n\n          -  Previous treatment with SPS.\n\n          -  Treatment with a drug or device within the last 30 days that has not received\n             regulatory approval at the time of study entry.\n\n          -  Subjects with cardiac arrhythmias that require immediate treatment.\n\n          -  Subjects on insulin where a stable dose has not yet been established.*\n\n          -  Subjects on dialysis. * Subjects on stable insulin or insulin analogues can be\n             enrolled. Subjects who have been on the same insulin dose and regimen for > 14 days\n             are considered stable. Whenever possible, all blood draws collected prior to meals\n             should be collected prior to insulin/insulin analogue treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01866709", 
            "org_study_id": "SPS-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sodium Polystyrene Sulfonate", 
                "intervention_name": "Sodium polystyrene sulfonate", 
                "intervention_type": "Drug", 
                "other_name": "SPS"
            }, 
            {
                "arm_group_label": "Silicified microcrystalline cellulose", 
                "intervention_name": "Silicified microcrystalline cellulose", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "August 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edgewater", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32132"
                }, 
                "name": "Riverside Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 4, Single-center, Prospective, Double-blind, Placebo-controlled, Randomized Study to Investigate the Safety and Efficacy of Sodium Polystyrene Sulfonate (SPS) in Subjects With Hyperkalemia.", 
        "overall_official": {
            "affiliation": "ZS Pharma, Inc.", 
            "last_name": "Henrik Rasmussen, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To perform a controlled evaluation of the safety and efficacy of 15g of SPS administered 3 times daily for 48 hours (6 doses) in patients with hyperkalemia (serum potassium levels between 5.0 - 6.5 mmol/l) at baseline.", 
            "measure": "Change in serum potassium levels from baseline after administration of sodium polystyrene sulfonate (SPS) three times a day.", 
            "safety_issue": "Yes", 
            "time_frame": "First 48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01866709"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Change in serum sodium, magnesium, calcium levels from baseline after administration of SPS.", 
            "safety_issue": "Yes", 
            "time_frame": "First 48 hours"
        }, 
        "source": "ZS Pharma, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ZS Pharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "August 2013", 
        "why_stopped": "Risk/benefit determinations in three subjects on SPS, study blind was broken."
    }
}